After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease, making it the first country with a rapidly aging population to have a treatment for the disease.
- Leqembi, developed by Japanese drugmaker Eisai Co. and US biotechnology firm Biogen Inc., is designed for patients in the early stages of Alzheimer's, helping to slow their cognitive decline. The approval was announced by Prime Minister Fumio Kishida.
- The number of dementia patients aged 65 or older in Japan is expected to rise to 7 million by 2025, highlighting the urgent need for treatments like Leqembi. Eisai Co. is dedicated to providing this new treatment to individuals and their families.
29 Articles
29 Articles
Japan Approves Alzheimer's Treatment Drug 'Leqembi' Amidst Aging Population Crisis
(CTN NEWS) – In a significant stride towards tackling Alzheimer’s disease, Japan’s Ministry of Health has given its seal of approval to Leqembi, a groundbreaking medication jointly developed by Japanese pharmaceutical giant Eisai Co. and the U.S. biotechnology firm Biogen Inc. This momentous decision marks a pivotal moment not only for Alzheimer’s treatment but also […]
After US approval, Japan OKs Leqembi, its first Alzheimer’s drug, developed by Eisai and Biogen
TOKYO (AP) — Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It’s the first drug for treatment of the disease in a country with a rapidly aging population. Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug’s approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administratio…
After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen
TOKYO (AP) -- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.
After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen
TOKYO (AP) -- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
